Dediabetes Logo
Preguntas
Respuestas publicadas conectadas con evidencia
Referencia clínica
Dossieres detallados de intervenciones y resultados
Investigacion reciente
Estudios mas recientes
Acerca de
Cómo funciona deDiabetes
Configuracion
Entrar / Unirse
Resumen de Investigación
Analyzed using Evidence Intelligence™

Survodutide improves HbA1c and bodyweight in type 2 diabetes

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

Última actualización 5 de julio de 2026

Key finding

HbA 1c decreased from baseline (mean ± SD 64.7 ± 9.2 mmol/mol) after 16 weeks’ treatment.

This Phase II study evaluated the effects of Survodutide on HbA1c levels and bodyweight in adults with Type 2 Diabetes, finding significant reductions in both outcomes compared to baseline.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This Phase II study evaluated the effects of Survodutide on HbA1c levels and bodyweight in adults with Type 2 Diabetes, finding significant reductions in both outcomes compared to baseline.

Clinical relevance

These findings are clinically significant as they suggest that Survodutide could be an effective treatment option for managing Type 2 Diabetes, potentially leading to better glycemic control and weight management for patients. Effective management of these parameters is crucial in reducing the risk of diabetes-related complications.

Keep in mind

The study did not include long-term follow-up data. Sample size and demographic diversity were not specified. Effectiveness of Survodutide compared to other treatments was not fully explored.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Matthias B, Julio R, Josef H, Raymond M, Anita MH. Survodutide Reduces HbA1c Levels and Bodyweight in Adults with Type 2 Diabetes: A Phase II Study. Diabetologia. 2023;67(3):470-482. doi:10.1007/s00125-023-06053-9

View DOIView on PubMedView on PMC

Efectos Principales

HbA1c decreased by -9.92 mmol/mol (p=0.001) after treatment with Survodutide.

Bodyweight decreased by up to -8.7% with Survodutide.

No significant change in HbA1c levels was observed in the placebo group.

Bodyweight change with Semaglutide was not significantly different from placebo.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide, Survodutide and Body weight, HbA1c.

This study contributes evidence to

Intervention

Semaglutide

Outcome

Body weight

Evidence topic

Weight Loss

Primary intervention

Semaglutide

Primary outcomes

  • Body weight
  • HbA1c

Evidence topics

Weight LossHbA1c ReductionGLP-1 Receptor Agonists

Primary intervention

Semaglutide

Primary outcomes

Body weightHbA1c

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

3
Evidence pairs
3
Relationships
3
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

3

Related topics

3

Evidence pairs

1079

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 3 evidence relationships
  • Includes primary outcome data
  • Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

GLP-1 Receptor Agonists and Body Weight

Evidencia relacionada

Tema de evidencia

Weight Loss

Guardar evidencia

Tema de evidencia

HbA1c Reduction

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

Body weight

Semaglutide → Body weight

Semaglutide → Body weight

Evidence Intelligence™
EvidenceScore™
86
Strong
ImpactScore™
76
Positive
ConsistencyScore™
92
consistent
Estudios de apoyo: Basado en 13 estudios
Add to Evidence Tracker

Body weight

Survodutide → Body weight

Survodutide → Body weight

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
50
Neutral
ConsistencyScore™
100
consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence Tracker

HbA1c

Survodutide → HbA1c

Survodutide → HbA1c

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
75
Positive
ConsistencyScore™
35
mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

La Evidencia Sugiere

  • Survodutide reduced HbA1c levels by -9.92 mmol/mol.
  • Bodyweight decreased by up to -8.7% with Survodutide.
  • Placebo showed no significant changes in HbA1c levels.
who this applies

A quién se aplica

  • Adults diagnosed with Type 2 Diabetes.
  • Individuals seeking new treatment options for diabetes management.
keep in mind

Tener en Cuenta

  • Results are based on a 16-week treatment period.
  • Findings may not be generalizable to all populations.
  • Further studies are needed to assess long-term effects and safety.
between the lines

Entre Líneas

  • The study did not include long-term follow-up data.
  • Sample size and demographic diversity were not specified.
  • Effectiveness of Survodutide compared to other treatments was not fully explored.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Do GLP-1 Receptor Agonists affect body weight?

Strong Evidence

GLP-1 Receptor Agonists may affect body weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Body weight

    EvidenceScore™ Strong | EvidenceScore™ 85.8 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 43 supporting studies with consistent results and a positive effect signal.

43 supporting studies
View Full Evidence

Does Survodutide lower HbA1c?

Moderate Evidence

Survodutide may lower HbA1c.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence

Does Survodutide affect body weight?

Moderate Evidence

Current evidence does not show a clear effect of Survodutide on body weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Body weight

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Weight Loss Evidence HubHbA1c Reduction Evidence HubGLP-1 Receptor Agonists Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Survodutide and HbA1cAll studies on Semaglutide and Body weightAll studies on Survodutide and Body weight

Related research

Read related research summaries.

Semaglutide may reduce cardiovascular events in non-diabetic patients.Survodutide improves insulin sensitivity in type 2 diabetesOral semaglutide reduces cardiovascular events in type 2 diabetesSemaglutide improves insulin sensitivity in adolescents with obesitySurvodutide may improve weight reduction in obesity with type 2 diabetes

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.